Literature DB >> 20714136

Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.

Lama A Noureddine1, Sohail A Usman, Zhangsheng Yu, Ranjani N Moorthi, Sharon M Moe.   

Abstract

BACKGROUND/AIMS: We have shown that hepatitis C does not increase the risk of developing chronic kidney disease (CKD), but it is not known if hepatitis C worsens progression of existing CKD.
METHODS: We retrospectively identified patients with primary glomerulonephritis on biopsy over 4 years, evaluating the progression of CKD over time.
RESULTS: The cohort consisted of 111 patients: 21% were positive for hepatitis C, 61% were negative for hepatitis C and 18% were not tested. The hepatitis C-positive subjects were more likely to be African American (p = 0.031), followed for fewer days (p = 0.007) and have diabetes and focal segmental glomerulosclerosis on biopsy (p < 0.001). Longitudinal follow-up of CKD progression using multiple creatinine measures analyzed by repeated measures ANCOVA demonstrated that patients with hepatitis C had a worsening creatinine over time compared to the hepatitis C-negative and not tested groups (p < 0.001). By Cox hazards regression analyses, risk of death/end-stage renal disease (ESRD) was decreased in patients who tested negative for hepatitis C compared to testing positive (0.46, CI 0.27-0.88), but this became nonsignificant after adjustment for mean arterial pressure and hemoglobin.
CONCLUSION: Our results support that infection with hepatitis C in patients with glomerulonephritis is associated with an increased risk of progression of CKD. Prospective studies are required to confirm these observations.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714136      PMCID: PMC2969148          DOI: 10.1159/000319456

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  23 in total

1.  Focal segmental glomerulosclerosis and hepatitis C virus: a case report.

Authors:  M Motta; M Malaguarnera; N Restuccia; M Romano; E Vinci; G Pistone
Journal:  Panminerva Med       Date:  2001-03       Impact factor: 5.197

2.  Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  D Sansonno; L Gesualdo; C Manno; F P Schena; F Dammacco
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

3.  Hepatitis C infection and membranoproliferative glomerulonephritis.

Authors:  J M Doutrelepont; M Adler; M Willems; P Durez; S H Yap
Journal:  Lancet       Date:  1993-01-30       Impact factor: 79.321

4.  Hepatitis C virus-associated tubulointerstitial injury.

Authors:  Kenji Kasuno; Takahiko Ono; Akira Matsumori; Fumiaki Nogaki; Hitoshi Kusano; Hitomi Watanabe; Junji Yodoi; Eri Muso
Journal:  Am J Kidney Dis       Date:  2003-04       Impact factor: 8.860

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Focal segmental glomerular sclerosis among patients infected with hepatitis C virus.

Authors:  C Stehman-Breen; C E Alpers; W P Fleet; R J Johnson
Journal:  Nephron       Date:  1999-01       Impact factor: 2.847

7.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.

Authors:  D M Burstein; R A Rodby
Journal:  J Am Soc Nephrol       Date:  1993-12       Impact factor: 10.121

8.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.

Authors:  R J Johnson; D R Gretch; H Yamabe; J Hart; C E Bacchi; P Hartwell; W G Couser; L Corey; M H Wener; C E Alpers
Journal:  N Engl J Med       Date:  1993-02-18       Impact factor: 91.245

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study.

Authors:  Michel Jadoul; Jean-Louis Poignet; Colin Geddes; Francesco Locatelli; Charlotte Medin; Magdalena Krajewska; Guillermina Barril; Ernst Scheuermann; Sandor Sonkodi; Patrick Goubau
Journal:  Nephrol Dial Transplant       Date:  2004-04       Impact factor: 5.992

View more
  11 in total

Review 1.  Hepatitis C virus infection and kidney disease: a meta-analysis.

Authors:  Fabrizio Fabrizi; Paul Martin; Vivek Dixit; Piergiorgio Messa
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

3.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 4.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Fabrizio Fabrizi; Simona Verdesca; Piergiorgio Messa; Paul Martin
Journal:  Dig Dis Sci       Date:  2015-07-21       Impact factor: 3.199

5.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

6.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

7.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

8.  Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection.

Authors:  Sara Yee Tartof; Jin-Wen Hsu; Rong Wei; Kevin B Rubenstein; Haihong Hu; Jean Marie Arduino; Michael Horberg; Stephen F Derose; Lei Qian; Carla V Rodriguez
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-21       Impact factor: 8.237

9.  Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease.

Authors:  T Li; K M Korenblat; K J Fowler; C Ho; A Liapakis; D Roth; J Yee; M C Politi; N George
Journal:  Pilot Feasibility Stud       Date:  2018-02-21

10.  A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.

Authors:  Yi-Chun Chen; Shang-Jyh Hwang; Chung-Yi Li; Chia-Pin Wu; Li-Chu Lin
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.